EP Patent

EP4215614A1 — Combination therapy for dystrophin-related diseases

Assigned to Dynacure · Expires 2023-07-26 · 3y expired

What this patent protects

The present invention relates to a new therapy for dystrophin-related diseases. More particularly, the present invention relates to a combination therapy for use in treating a dystrophin-related myopathy in a subject in need thereof, said therapy comprising (i) a dynamin 2 inhibi…

USPTO Abstract

The present invention relates to a new therapy for dystrophin-related diseases. More particularly, the present invention relates to a combination therapy for use in treating a dystrophin-related myopathy in a subject in need thereof, said therapy comprising (i) a dynamin 2 inhibitor and (ii) a therapy providing or restoring a functional dystrophin in the subject.

Drugs covered by this patent

Patent Metadata

Patent number
EP4215614A1
Jurisdiction
EP
Classification
—
Expires
2023-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Dynacure
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.